NDLI: TNF antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.

Please wait, while we are loading the content...

Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion.

Development of natural calcium- and phosphate-donating microparticles and a new iontophoretic apparatus for the topical treatment of local osteoporosis. Preliminary in vitro and in vivo studies.

Mseleni joint disease: a potential model of epigenetic chondrodysplasia.

Gait analysis as a quantifiable outcome measure in hip or knee osteoarthritis: a systematic review.

Unusual foreign body granuloma (gauzoma) found 46 years after open reduction and fixation surgery for femoral shaft fracture.

Usefulness of the cytology in the diagnosis of bone lesions.

Schnitzler's syndrome improvement after anti-TNF-alpha therapy.

Dupuytren's contracture limited to the distal interphalangeal joint: a case report.

Articular angioleiomyoma presenting as cyclic hip pain.

Inflammatory myofibroblastic tumour of the tibia.

Is the family history positive for SLE a predisposing factor for anti-TNFalpha blockers induced lupus? A case report.

Steroid-responsive dropped-head-syndrome due to polymyositis.

TNF antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.

Lytic lesion in the second metacarpal.

Axial osteomalacia: a new case report.

Silica-associated limited systemic sclerosis after occupational exposure to calcined diatomaceous earth.

Osteoporotic vertebral fractures: a role for vertebroplasty or kyphoplasty?

High frequency of vitamin D insufficiency in primary antiphospolipid syndrome.

Treatment of inflammatory muscle disease in adults.

Anti-CRP antibodies in systemic lupus erythematosus.

Chronic eosinophilic pneumonia (Carrington's disease) and rheumatoid arthritis.

Xiphodynia and prominence of the xyphoid process. Value of xiphosternal angle measurement: three case reports.

Looking for microRNA polymorphisms as new rheumatoid arthritis risk loci?

Septic arthritis of the acromioclavicular joint.

Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?

Henri Bergson's rheumatoid arthritis.

Efficacy of a functional restoration program for chronic low back pain: prospective 1-year study.

Management recommendations for knee osteoarthritis: how usable are they?

Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.

Feasibility and safety of ultrasound-guided caudal epidural glucocorticoid injections.

A polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility.

Year: 2010 Volume: 77 Issue: 4

Year: 2010 Volume: 77 Issue: 3

Year: 2010 Volume: 77 Issue: 2

Year: 2010 Volume: 77 Issue: Supplementary 2

Year: 2010 Volume: 77 Issue: 1

Year: 2010 Volume: 77 Issue: Supplementary 1

Year: 2009 Volume: 76

Year: 2008 Volume: 75

Year: 2005 Volume: 72

TNF antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Couderc, Marion Payet, Sarah Henquell, Cécile Dubost, Jean-Jacques Soubrier, Martin
Description	Country affiliation: France Author Affiliation: Couderc M ( Service de rhumatologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France. mcouderc@chu-clermontferrand.fr)
Abstract	OBJECTIVE: The risk of non-Hodgkin lymphoma is increased in rheumatoid arthritis (RA) but not in ankylosing spondylitis (AS). In RA, the degree of inflammation is closely associated with the lymphoma risk. Whether immunosuppressants such as methotrexate and TNF antagonists affect the lymphoma risk in RA is unclear. The Epstein-Barr virus (EBV) may contribute to the pathogenesis of RA and may be involved in the development of lymphoma in patients taking methotrexate and/or TNF antagonists, although these points remain debated. EBV load monitoring during immunosuppressive treatment may predict the occurrence of EBV-related lymphoma. Here, our objective was to prospectively measure the EBV load in patients receiving TNF antagonists for RA or AS. METHODS: We prospectively studied patients with RA or AS before and after TNF antagonist therapy initiation. The EBV load was measured in blood samples using the EBV R-gene Quantification Kit. Disease activity at the time of blood sampling was evaluated by determining the Disease Activity Score 28 (DAS28) in RA patients and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS patients. RESULTS: We included 46 patients with RA (82.6% women; mean age, 52.7 ± 11.3 years) and 27 with AS (men, 81.5%; mean age, 45.1 ± 12.7 years). In the RA group, the EBV load was measured at baseline and 9.72 ± 5.7 months later. The baseline EBV load was undetectable in 33 (70.2%) patients; mean EBV load in the 13 remaining patients was 9389 copies/ml (3.47 log10 ± 0.45). Baseline EBV load did not correlate with disease activity (DAS28). At the follow-up assay, the EBV load became positive in five patients and increased significantly in one patient (four patients on etanercept, one on adalimumab, and one on infliximab); it became negative in six patients (five on adalimumab and one on etanercept) and showed non-significant changes in six patients. Mean EBV load in patients positive at follow-up was 3.63 ± 0.52 log10 copies/ml. Mean DAS28 was 4.78 ± 1.1 at baseline and 2.94 ± 1.24 at follow-up. At follow-up, a good EULAR response was noted in 33 (71.7%) patients and a moderate EULAR response in seven (15.2%) patients. In the AS group, the baseline EBV load measurement occurred after 12.9 ± 10.6 months. Baseline EBV load was undetectable in 25 (92.6%) patients; mean load in the remaining two patients was 4.15 ± 0.46 log10 copies/ml. At follow-up, the EBV load became positive in two patients (one on adalimumab and one on infliximab) and became negative in one patient (on adalimumab). Mean load in positive patients was 3.33 ± 0.24 log10 copies/ml. Mean BASDAI was 55.1 ± 16.2 at baseline and 17.88 ± 18.62 at follow-up. A positive EBV load was significantly more common in the RA group than in the AS group (P = 0.039). EBV load changes did not differ significantly between the RA and AS groups or across TNF antagonists. No cases of lymphoma were recorded. CONCLUSION: Introducing TNF antagonist therapy does not affect the EBV load in patients with RA or AS. EBV load monitoring is probably unnecessary in patients given TNF antagonists for RA or AS.
File Format	HTM / HTML
ISSN	1297319X
Issue Number	5
Volume Number	77
e-ISSN	17787254
Journal	Joint Bone Spine
Language	English
Publisher	Elsevier
Publisher Date	2010-10-01
Publisher Place	France
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Rheumatology Antirheumatic Agents Pharmacology Arthritis, Rheumatoid Virology Spondylitis, Ankylosing Tumor Necrosis Factor-alpha Antagonists & Inhibitors Viral Load Drug Effects Adalimumab Adult Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Therapeutic Use Etanercept Female Herpesvirus 4, Human Humans Immunoglobulin G Infliximab Lymphoma, Non-hodgkin Male Middle Aged Prospective Studies Receptors, Tumor Necrosis Factor Journal Article
Content Type	Text
Resource Type	Article
Subject	Rheumatology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.

Estimated medication costs of primary TNF antagonist failure in patients with rheumatoid arthritis.

Anti-TNF therapy.

TNF alpha antagonist therapy and safety monitoring.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Economic impact of rheumatoid arthritis (RA) biotherapies in France.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

TNF antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.

Similar Documents

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.

Estimated medication costs of primary TNF antagonist failure in patients with rheumatoid arthritis.

Anti-TNF therapy.

TNF alpha antagonist therapy and safety monitoring.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Economic impact of rheumatoid arthritis (RA) biotherapies in France.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

TNF antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.